Among patients with melanoma for whom anti-PD-1/PD-L1 treatment was ineffective (clinicaltrials.gov trial no. NCT01968109), the combination of BMS-986016 and an anti-PD-1 agent (nivolumab) demonstrated a good effect with safety similar to that of nivolumab monotherapy. The gene discussed is CD274; the disease is melanoma.